Loading
A lab test that measures how close a leukaemia cell is to self-destructing, and which survival protein is holding it back, to predict response to venetoclax-type drugs.
Permeabilised cells are exposed to BH3 peptides; mitochondrial depolarisation reveals dependence on BCL-2, BCL-XL, or MCL-1. Predicted venetoclax response in AML and CLL in research cohorts and explains MCL-1-mediated resistance. Being commercialised as a companion tool for BH3-mimetic selection and combination design.
Dynamic BH3 profiling quantifies 'priming' for apoptosis after brief drug exposure.
Query for this technology: (TITLE:"BH3 profiling" OR ABSTRACT:"BH3 profiling" OR TITLE:"functional apoptosis testing" OR ABSTRACT:"functional apoptosis testing") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BH3 profiling (functional apoptosis testing), not a curated reading list.
Shares Sonrotoclax, Intrinsic apoptosis (BCL-2 family), BCL-2 inhibitors, BCL-2.
Shares Sonrotoclax, Intrinsic apoptosis (BCL-2 family), BCL-2 inhibitors, BCL-2.
Shares Sonrotoclax, BCL-2 inhibitors, BCL-2, Venetoclax.
Shares Test drugs on the patient's own cancer cells when there is no trial to join, Functional (ex vivo) drug testing, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Lab models that fail to predict what happens in patients.
Shares Sonrotoclax, BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia.
Shares Sonrotoclax, BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia.
Shares Test drugs on the patient's own cancer cells when there is no trial to join, Functional (ex vivo) drug testing, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Lab models that fail to predict what happens in patients.
Shares Ex vivo drug sensitivity screening in blood cancers (EXALT), Functional (ex vivo) drug testing, Acute myeloid leukaemia.